Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2015 Oct 8

PMID 26442621

Citations 5

Authors

Chuannan Zhai

Hongliang Cong

Yujie Liu

Ying Zhang

Xianfeng Liu

Hao Zhang

Zhijing Ren

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have showed that high-dose statin pretreatment could reduce the incidence of periprocedural myocardial infarction (PMI) in patients undergoing percutaneous coronary intervention (PCI). However, previous analyses have not performed reliable grading of evidence.

Hypothesis: In previous analyses, it supposed that the high-dose statin pretreatment was effective in reduction of the rate of PMI. In this analysis, we evaluated the effect of high-dose statin pretreatment on the reduction of rate of PMI based on a cumulative meta-analysis and grading of evidence.

Methods: We assembled the relevant published randomized controlled trials that compared the efficacy of high-dose statin pretreatment prior to PCI. We evaluated the risk of PMI by a cumulative meta-analysis, with subgroups stratified by clinical classifications and different statin histories, and we conducted explicit grading of evidence.

Results: High-dose statin pretreatment caused a 55% reduction in PMI through this cumulative meta-analysis of 23 RCTs (odds ratio [OR]: 0.45, 95% confidence interval [CI]: 0.37-0.54). The effect of high-dose statin pretreatment was significant for the stable angina subgroup (OR: 0.42, 95% CI: 0.32-0.56), ACS subgroup (OR: 0.43, 95% CI: 0.29-0.64), and the mixed presentation subgroup (OR: 0.50, 95% CI: 0.36-0.70). In different statin therapy histories, high-dose statin pretreatment reduced incidence of PMI 55% in the statin-naive subgroup (OR: 0.45, 95% CI: 0.36-0.56) and 54% in the low-dose statin subgroup (OR: 0.46, 95% CI: 0.32-0.66). The GRADE system indicated that the overall evidence quality was moderate. This finding may strengthen the confidence in any recommendations.

Conclusions: High-dose statin pretreatment can reduce the rate of PMI, irrespective of either the clinical presentation or previous statin-treatment history. Importantly, the overall GRADE evidence quality was moderate.

Citing Articles

Efficacy of single high-dose statin prior to percutaneous coronary intervention in acute coronary syndrome: a systematic review and meta-analysis.

de Liyis B, Jagannatha G, Kosasih A, Darma I, Artha I Egypt Heart J. 2024; 76(1):49.

PMID: 38630377 PMC: 11024076. DOI: 10.1186/s43044-024-00481-7.

Associations of pre-hospital statin treatment with in-hospital outcomes and severity of coronary artery disease in patients with first acute coronary syndrome-findings from the CCC-ACS project.

Zhang L, Zhang Y, Chu C, Deng F, Zhou J, Yuan Z Front Cardiovasc Med. 2023; 9:1030108.

PMID: 36741846 PMC: 9889368. DOI: 10.3389/fcvm.2022.1030108.

Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention.

Fici F, Faikoglu G, Tarim B, Robles N, Tsioufis K, Grassi G High Blood Press Cardiovasc Prev. 2022; 29(2):137-144.

PMID: 35064911 DOI: 10.1007/s40292-021-00496-0.

Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial.

Pourhosseini H, Lashkari R, Aminorroaya A, Soltani D, Jalali A, Tajdini M Int J Cardiol Heart Vasc. 2019; 22:96-101.

PMID: 30671535 PMC: 6328087. DOI: 10.1016/j.ijcha.2018.12.003.

Predictive value of baseline C-reactive protein for periprocedural myocardial infraction of higher risk stratifications: A retrospective cohort clinical study.

Yao M, Zhao L, Wu L, Zhang W, Luan Y, Song J Anatol J Cardiol. 2018; 20(6):310-317.

PMID: 30297597 PMC: 6287438. DOI: 10.14744/AnatolJCardiol.2018.05406.

References

Ioannidis J, Karvouni E, Katritsis D . Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol. 2003; 42(8):1406-11. DOI: 10.1016/s0735-1097(03)01044-1. View

Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S . Grading quality of evidence and strength of recommendations. BMJ. 2004; 328(7454):1490. PMC: 428525. DOI: 10.1136/bmj.328.7454.1490. View

Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G . Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004; 110(6):674-8. DOI: 10.1161/01.CIR.0000137828.06205.87. View

Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P . Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004; 25(20):1822-8. DOI: 10.1016/j.ehj.2004.07.017. View

Herrmann J . Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005; 26(23):2493-519. DOI: 10.1093/eurheartj/ehi455. View

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49(12):1272-8. DOI: 10.1016/j.jacc.2007.02.025. View

Kinoshita M, Matsumura S, Sueyoshi K, Ogawa S, Fukuda K . Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention?. Circ J. 2007; 71(8):1225-8. DOI: 10.1253/circj.71.1225. View

Bozbas H, Yildirir A, Mermer S, Konas D, Atar I, Aydinalp A . Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention?. Adv Ther. 2007; 24(3):493-504. DOI: 10.1007/BF02848771. View

Jia X, Fu X, Zhang J, Gu X, Fan W, Wu W . Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J (Engl). 2009; 122(6):659-64. View

10.

Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A . Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009; 54(6):558-65. DOI: 10.1016/j.jacc.2009.05.028. View

11.

Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A . Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009; 54(23):2157-63. DOI: 10.1016/j.jacc.2009.07.005. View

12.

Cay S, Cagirci G, Sen N, Balbay Y, Durmaz T, Aydogdu S . Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin. Cardiovasc Drugs Ther. 2010; 24(1):41-7. DOI: 10.1007/s10557-010-6224-1. View

13.

Yun K, Oh S, Rhee S, Yoo N, Kim N, Jeong J . 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2010; 146(1):68-72. DOI: 10.1016/j.ijcard.2010.04.052. View

14.

Toso A, Leoncini M, Maioli M, Gallopin M, Tedeschi D, Amato M . Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. J Cardiovasc Med (Hagerstown). 2010; 12(5):318-21. DOI: 10.2459/JCM.0b013e328341024f. View

15.

Lansky A, Stone G . Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010; 3(6):602-10. DOI: 10.1161/CIRCINTERVENTIONS.110.959080. View

16.

Yu X, Zhang H, Ren S, Geng J, Wu T, Chen W . Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis. 2010; 22(1):87-91. DOI: 10.1097/MCA.0b013e328341baee. View

17.

Guyatt G, Oxman A, Vist G, Kunz R, Brozek J, Alonso-Coello P . GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011; 64(4):407-15. DOI: 10.1016/j.jclinepi.2010.07.017. View

18.

Veselka J, Zemanek D, Hajek P, Maly M, Adlova R, Martinkovicova L . Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention. Am J Cardiol. 2011; 107(9):1295-9. DOI: 10.1016/j.amjcard.2010.12.040. View

19.

Patti G, Cannon C, Murphy S, Mega S, Pasceri V, Briguori C . Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011; 123(15):1622-32. DOI: 10.1161/CIRCULATIONAHA.110.002451. View

20.

Fujii K, Kawasaki D, Oka K, Akahori H, Iwasaku T, Fukunaga M . The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2011; 4(5):513-20. DOI: 10.1016/j.jcin.2011.02.005. View